| Literature DB >> 33349812 |
Chuanxiong Nie1, Lang Ma2, Hongrong Luo3, Jinku Bao4, Chong Cheng1.
Abstract
The outbreak of a novel highly infectious virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has aroused people's concern about public health. The lack of ready-to-use vaccines and therapeutics makes the fight with these pathogens extremely difficult. To this point, rationally designed virus entry inhibitors that block the viral interaction with its receptor can be novel strategies to prevent virus infection. For ideal inhibition of the virus, the virus-inhibitor interaction has to outperform the virus-host interaction. In our view, the morphology of the inhibitor should be carefully designed to benefit virus-inhibitor binding, especially that the surfaces of viruses are mostly rough due to the existence of surface proteins for receptor-binding. In this perspective article, we would like to discuss the recent progress of designing inhibitors with spiky topography to maximize the interactions between viruses and inhibitors. We also would like to share our idea for the future study of inhibitors to prevent virus infection.Entities:
Keywords: Infection prevention; Inhibitor; Public health; Spiky nanostructures; Virus binding
Year: 2020 PMID: 33349812 PMCID: PMC7363616 DOI: 10.1016/j.smaim.2020.07.004
Source DB: PubMed Journal: Smart Mater Med ISSN: 2590-1834
Scheme 1The general concepts of using spiky nanostructures for inhibiting virus binding to cell membranes.
Fig. 1(a) Typical cryo-EM image for an IAV virion. Scale bar: 50 nm. (b) Morphological illustration of a spiky nanoparticle interacting with an IAV virion. (c) Interaction between IAV virion and spiky nanoparticles with different geometry parameters. Reprinted with permission from Ref. [15]. Copyright (2020) American Chemical Society.
Fig. 2(a) High-resolution TEM images for the synthesized nanoparticles with different surface morphologies. Scale bar: 50 nm. The number in the nomenclature reveals the length of the spike. (b) A western blot based assay for the virus binding the nanoparticles. (c) Cryo-TEM images for the IAV virion binding to the spiky nanostructures. Scale bar: 50 nm. Reprinted with permission from Ref. [15]. Copyright (2020) American Chemical Society.
Fig. 3(a) Preparation of the EM coated spiky nanoparticles for virus inhibition and IAV virion binding the EM vesicles. Scale bar: 100 nm. (b, c) Immunofluorescent staining for the virus infection in the presence of the inhibitors. (d–e) Inhibition of virus replication in the presence of the inhibitors. Reprinted with permission from Refs. [15]. Copyright (2020) American Chemical Society.
Fig. 4(a) Molecules for the development of hetero-multivalent nano-inhibitor towards IAV. (b) Schematic illustration of the virus binding to the hetero-multivalent nano-inhibitor. (c) A western blot based assay for IAV binding to the nano-inhibitor. NP: smooth nanoparticle. VLNP: virus-like spiky nanoparticle. (d) Cryo-EM images for the virus binding the nano-inhibitor. Scale bar: 100 nm. (e) Inhibition of the NA activity for by the nano-inhibitors. (f) Inhibition of influenza A/X31 (H3N2) replication by the nano-inhibitors. (g) Inhibition of influenza A/X31 (H3N2), A/PR/8/34 (H1N1) and A/Panama/2007/1999 (H3N2) replication by the nano-inhibitors. (h) Plaque reduction efficiency for the nano-inhibitors. Reprinted with permission from Ref. [17]. Copyright (2020) Wiley.